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Modern molecular biology is geared
towards genes and proteins, with
small-molecule chemistry coming in a
distant third. Small molecules are
important as drugs, but largely ignored
in understanding how the cell works. 
The revival of small molecules
started with the discovery that
endothelium-relaxing factor, so
important for controlling blood
pressure, was nitric oxide (NO). With
a string of recent discoveries,
superoxide (O2.–) has now taken
center stage. This oxygen radical has
been implicated in a long list of
normal and disease processes,
including reperfusion injury (when a
blood supply is re-established
following surgery, a heart attack, or
stroke), neurodegenerative and
autoimmune diseases, and
inflammatory and mitogenic signaling.
Getting rid of superoxide has become
a major priority.
A low level of superoxide is
constantly generated by aerobic
respiration. The electron-transport
chain of mitochondria, which is meant
to escort four electrons to molecular
oxygen to form water, occasionally
leaks a single electron. “It’s like a
wire with insufficient insulation,” says
Irwin Fridovich of Duke University,
Durham, North Carolina. 
In 1969 Fridovich and Joe McCord
(University of Colorado Health
Sciences Center, Denver) discovered
the body’s primary mode of defense
against this leakage: superoxide
dismutase (SOD). SOD converts
superoxide to hydrogen peroxide
(H2O2) and molecular oxygen. It is
remarkable for its use of electrostatic
guidance of substrates to exceed
diffusion-limited catalytic rates. But as
a treatment SOD was found wanting
— it was unstable, didn’t penetrate
into cells, and provoked an immune
response. Now a group of companies,
including MetaPhore
Pharmaceuticals, Inc. (St Louis,
Missouri), is trying to mimic the SOD
enzyme with cell-permeable small
molecules. MetaPhore’s human
testing is only scheduled to start late
in 2000, but already, says Fridovich,
“they’ve had good success. The
principle has been proven.”
Enzyme design
Metals are good at doing redox
chemistry, but indiscriminate redox
chemistry by free metals is very toxic
to the cell. Therefore, says
MetaPhore’s vice-president of
research Dennis Riley, “if you’re
going to have a metal as a redox drug
you need to have it in a stable ligand.
The way to do it is the way nature
does it — with a macrocycle.”
Small molecules that mimic
enzymes can destroy disease-
causing radicals.
Riley started with manganese,
which is far less toxic than copper or
iron, the other two metals used in
native SODs. In his first series of
macrocycles there was just one
structure — a cyclic penta-aza
compound — that was both
catalytically active and reasonably
stable (Figure 1). 
Improving on the initial
compound took an understanding of
the reaction mechanism. Riley found
that the rate-limiting step of the
reaction cycle was the oxidation of
the Mn(II) state to the Mn(III) state.
In the Mn(II) state the five nitrogen
ligands were in a single plane, with
two additional Mn ligands above and
below this plane. But in the Mn(III)
state one of these axial ligands was
replaced by one of the five nitrogens.
Riley realized that in an efficient
enzyme, “you don’t have time for the
ligand to change shape. You have to
hold the precursor in a geometry that
is the same shape as the product.”
He therefore added substituents to
hold the Mn(II) compound in a
folded conformation, with one of the
nitrogens out of the plane, ready for
the conversion to the Mn (III) state.
“Our compound behaves like an
enzyme — it holds a ligand in a pre-
organized state that it may not
otherwise favor,” says Riley.
“They’re truly little synthetic
enzymes. They’re just not made by
transcription of DNA.”
No room at the inn
The rational design process was a
success, but the project was fighting
for the attention of Riley’s employer,
the Monsanto Company (St. Louis,
Missouri). Monsanto’s pharmaceutical
subsidiary, Searle, had several
potential blockbusters on its hands,
including the now highly successful
Cox2-specific anti-inflammatory drug
Celebrex. With the stakes in this
market so high the company was,
according to Riley, “shooting for the
moon. They were trying to do
everything in parallel, so there wasn’t
a way to do our program.”
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Figure 1
One of the macrocycle SOD mimics under
investigation at MetaPhore. The two
cyclohexano groups (bottom right and left) keep
the molecule in a bent conformation that mimics
the Mn(III) state, therefore speeding the rate-
limiting Mn(II) to Mn(III) oxidation reaction. The
curvature is robust enough to withstand the
planar-favoring effects of the pyridine group
(top), which was added to increase stability.
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Monsanto offloaded the SOD
technology to a small company called
MetaPhore, which was already looking
for metal chelates to treat the iron-
overload disease hemachromatosis. “I
was quite shocked and demoralized,”
says Riley. But Monsanto retained only
a few royalties and the right of first
offer in any buy-back deal, so in the
end, says Riley, the freedom turned
out to be “so much the better for us.”
Further improvement of
MetaPhore’s lead compound has
relied on knowledge of the reaction
mechanism and a resulting computer
model, says Riley. “Without it there
was no way we would have had
enough chemists to test a random
empirical series.”
The end result is a compound
with a catalytic rate constant that
exceeds 109 M–1 s–1, which is ten
times faster than the original Mn-
based protein. “You need a very fast
catalyst to interfere with the chain
reactions started by superoxide,”
says Riley. With that in hand, Riley is
ready for clinical trials.
So many diseases, so little time
Soon after its discovery as a
byproduct of oxidative metabolism,
superoxide began turning up in
many biological systems: as a product
of NADPH oxidase in phagocytes,
which use a burst of superoxide to
help kill bacteria; in signaling
cascades involving NFKB in immune
cells and ras in cancer cells; and after
reperfusion or brain excitotoxicity
when metabolism is suddenly
resumed or increased. 
Thus the list of diseases that may
be treatable with SOD mimics now
includes heart attacks, stroke,
autoimmune diseases (such as
osteoarthritis), neurodegenerative
diseases (including Alzheimer’s and
Parkinson’s) and aging. 
MetaPhore is in the process of
choosing its disease target. The
company’s current leads are not orally
bioavailable, so it may decide on an
accessible target like radiation-
treatment-induced injury in cancer,
which is an early indication for the
compounds of Eukarion Inc. (Bedford,
Massachusetts). Eukarion is also
interested in neurodegenerative
diseases, as their compounds reach the
central nervous system. In these
longer-term applications there will be
more concern about immune
suppression, although Eukarion vice
president of research Susan Doctrow
says her company has not seen signs of
immune problems in animal models. 
My radical is fiercer than your radical
Eukarion started with Mn salen
compounds made by Eric Jacobsen
(Harvard University, Cambridge,
Massachusetts) as catalysts for
asymmetric epoxidation. The
compounds already had SOD activity,
but the company modified them to
increase catalase activity — the ability
to break down hydrogen peroxide.
“We believe the catalase activity in
some instances is more important,”
says Doctrow. But Riley says “the only
time [hydrogen peroxide] is a real
problem is when you have superoxide
around,” because the superoxide
reduces Fe(III) to Fe(II), releasing the
iron from storage sites so that it can
react with hydrogen peroxide and
produce hydroxyl radicals. 
John Groves at Princeton
University (Princeton, New Jersey)
has yet another target. Peroxynitrite
(ONOO–) is formed extremely rapidly
when superoxide combines with NO.
In trying to destroy superoxide before
it combines with NO, “you’re trying
to buck against a very fast reaction,”
says Groves, whose peroxynitrite
scavengers are being developed by
Inotek Corporation of Beverly,
Massachusetts. “It’s not clear how
many reactions superoxide does by
itself,” he says. “It could be that
peroxynitrite is a major part of the
story. There’s some sorting out to be
done.” 
As the companies fine-tune their
respective compounds, that sorting out
will become easier to do. Numerous
animal tests of SOD mimics have
been published, but Riley says the
latest tests by MetaPhore made it into
Science (286, 304–306 (1999)) because
“it was the first time that a molecule
was a totally selective SOD catalyst.
And by eliminating the superoxide we
eliminated the production of pro-
inflammatory cytokines. Providing
that link that superoxide is directly
responsible for turning on these pro-
inflammatory cytokines is very
important.”
A similar analysis should be
possible for each damage reaction.
“Armed with these compounds one
can begin to sort out how much of the
superoxide damage is through the
peroxynitrite reaction,” says Groves.
“Just as important as the potential
therapeutic applications of these
agents, they’re certainly going to be
very important in deconvoluting the
very complicated effects of [different
reactive chemicals] in the cell.”
A simple target
Fridovich has his own commercial
interests — his porphyrin-like SOD
mimics are being investigated by
Aeolus Pharmaceuticals, Inc.
(Research Triangle Park, North
Carolina) — and he thinks that
companies making SOD mimics
have chosen their target well. “You’re
mimicking the reaction catalyzed by
an intensely simple enzyme,” he
says. With only two reactants, “the
catalyst is just taking the electron
from one to another. If it was a more
complicated organic reaction it would
be hopeless. We have a particularly
easy target to mimic.”
If the chemistry is easy, perhaps it
can be tailored to cure the ultimate
modern obsession: aging.
“Everybody is very well aware of the
potential of free radicals in aging,”
says MetaPhore’s director of biology
Daniela Salvemini. As a company, she
says, “you have to have priorities.
Aging for now is not one of ours.” But
sooner rather than later, one would
suspect, the aging specter will arise.
After all, as Riley says, “these free
radical reactions are the death of us.”
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